Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year a...

Descripción completa

Detalles Bibliográficos
Autores: Pradenas, Edwards|||0000-0001-5162-8920, Trinité, Benjamin|||0000-0003-3809-042X, Urrea, Víctor|||0000-0002-2577-856X, Marfil, Sílvia|||0000-0003-0139-5000, Tarrés-Freixas, Ferran|||0000-0002-1569-0126, Ortiz, Raquel|||0000-0002-6919-2026, Rovirosa, Carla|||0000-0002-7111-0253, Rodon, Jordi|||0000-0002-1032-9091, Vergara-Alert, Júlia|||0000-0001-7484-444X, Segalés Coma, Joaquim|||0000-0002-1539-7261, Guallar, Victor|||0000-0002-4580-1114, Valencia, Alfonso|||0000-0002-8937-6789, Izquierdo Useros, Nuria|||0000-0002-1039-1821, Noguera-Julian, Marc|||0000-0002-6194-1395, Carrillo, Jorge|||0000-0003-0221-5948, Paredes, Roger|||0000-0002-6553-691X, Mateu, Lourdes|||0000-0001-7223-7611, Chamorro, Anna, Toledo, Ruth, Massanella, Marta|||0000-0002-3326-151X, Clotet Sala, Bonaventura|||0000-0003-3232-4598, Blanco, Julià|||0000-0002-2225-0217
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:257275
Acceso en línea:https://ddd.uab.cat/record/257275
https://dx.doi.org/urn:doi:10.1016/j.xcrm.2022.100523
Access Level:acceso abierto
Palabra clave:B cell memory
Durability
Half-life
Humoral response
Neutralizing antibodies
Pseudovirus
SARS-CoV-2
Severity
Variants of concern
Descripción
Sumario:To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year after symptom onset. We evaluate plasma-neutralizing activity using HIV-based pseudoviruses expressing the spike of different SARS-CoV-2 variants and analyze them longitudinally using mixed-effects models. Long-term neutralizing activity is stable beyond 1 year after infection in mild/asymptomatic and hospitalized participants. However, longitudinal models suggest that hospitalized individuals generate both short- and long-lived memory B cells, while the responses of non-hospitalized individuals are dominated by long-lived B cells. In both groups, vaccination boosts responses to natural infection. Long-term (.